Vimta Labs Reports Record Q1 Revenue of INR 993 Million, Up 31.4% Year-on-Year Jul 25, 2025
More news about Vimta Labs
17Jul 25
Vimta Labs Reports 35% Surge in Q1 Net Profit, Revenue Up 31%, EBITDA Grows
Vimta Labs announced impressive Q1 financial results, with net profit rising 35% to ₹189.00 crore. Revenue increased by 31% to ₹976.00 crore, while EBITDA grew 30% to ₹337.00 crore. The company's EBITDA margin stood at 34.53%, slightly lower than the previous year's 34.63%. These results indicate significant growth in Vimta Labs' operations and profitability.
Vimta Labs Reports Strong FY25 Results, Targets Revenue of Over Rs. 500 Crore by FY 2025-26
Vimta Labs Limited reported robust financial results for FY25 with total income up 19.1% to Rs. 3,482.22 crore and net profit increasing 36.8% to Rs. 667.55 crore. The company announced strategic initiatives including a 1:1 bonus share issue and plans to enter Biologics Contract Research and Development with a Rs. 50 crore investment. Vimta Labs set an ambitious revenue target of exceeding Rs. 500 crore by FY26 and declared a final dividend of Rs. 2 per equity share for FY25.
Vimta Labs has recommended a 1:1 bonus share issue and reported impressive financial results for FY 2024-25. Total income reached ₹3,482.22 crore, up 19.1% YoY, with PAT at ₹667.55 crore, up 36.8% YoY. The company declared a final dividend of ₹2 per share. Other key developments include expansion into Biologics CDMO, increased borrowing limit to ₹300 crore, appointment of new Secretarial Auditors, and reappointment of an Independent Director.
28Apr 25
Vimta Labs Reports Strong Q4 FY25 Results, Announces Bonus Shares and Expansion into Biologics
Vimta Labs reported robust Q4 and FY25 results with total income reaching ₹3,482.22 crore, up 19.1% year-on-year. Q4 FY25 saw a 31.4% increase in total income to ₹960.81 crore. The company declared a final dividend of ₹2 per share and recommended a 1:1 bonus share issue. Strategic initiatives include a ₹50 crore investment in Biologics CDMO, increased borrowing powers to ₹300 crore, and reappointment of Dr. Yadagiri R Pendri as Independent Director. Operational highlights include successful regulatory audits and expansion of laboratory spaces.
23Apr 25
Vimta Labs to Consider Q4 Results, Dividend, and Bonus Share Issue on April 28
Vimta Labs Limited has scheduled a board meeting for April 28, 2025, to approve Q4 and FY2025 financial results, consider dividend payment, and discuss a potential bonus share issue. The company has implemented a trading window closure from April 1, 2025, until 48 hours after the financial results announcement, in compliance with SEBI regulations.